Kanada - engleski - Health Canada

mylan pharmaceuticals ulc - risperidone - tablet (orally disintegrating) - 3mg - risperidone 3mg - atypical antipsychotics

Kanada - engleski - Health Canada

mylan pharmaceuticals ulc - risperidone - tablet (orally disintegrating) - 4mg - risperidone 4mg - atypical antipsychotics

Kanada - engleski - Health Canada

pharmel inc - risperidone - tablet (orally disintegrating) - 0.5mg - risperidone 0.5mg - atypical antipsychotics

Kanada - engleski - Health Canada

pharmel inc - risperidone - tablet (orally disintegrating) - 1mg - risperidone 1mg - atypical antipsychotics

Kanada - engleski - Health Canada

pharmel inc - risperidone - tablet (orally disintegrating) - 2mg - risperidone 2mg - atypical antipsychotics

Kanada - engleski - Health Canada

dominion pharmacal - risperidone - tablet (orally disintegrating) - 0.5mg - risperidone 0.5mg - atypical antipsychotics

Kanada - engleski - Health Canada

dominion pharmacal - risperidone - tablet (orally disintegrating) - 1mg - risperidone 1mg - atypical antipsychotics

Kanada - engleski - Health Canada

dominion pharmacal - risperidone - tablet (orally disintegrating) - 2mg - risperidone 2mg - atypical antipsychotics

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

a-s medication solutions - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone orally disintegrating tablets are indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)] . monotherapy risperidone orally disintegrating tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies (14.2)] . adjunctive therapy risperidone orally disintegrating tablets adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3)] . risperidone orally disintegrating tablets are indicated for the treatment of irritability associated w

Malezija - engleski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

mansa healthcare sdn bhd - risperidone -